---

GAMMA KNIFE IN ENT - A COMPREHENSIVE DISCUSSION (50 Marks)

---

1. INTRODUCTION AND HISTORICAL BACKGROUND

• Concept first introduced in 1951 by Lars Leksell (Swedish neurosurgeon), who coupled a stereotactic device to an orthovoltage X-ray tube and treated trigeminal neuralgia
• In 1968, Leksell introduced the first dedicated Gamma Knife unit with multiple Co-60 sources
• The device was brought to the United States in 1987 (University of Pittsburgh - Lunsford group, still the largest published series)
• Leksell coined the term "radiosurgery" - meaning the use of single-fraction, high-dose stereotactic ionizing radiation to destroy or inactivate a target

---

2. PHYSICS AND TECHNICAL BASIS

Principle

"The primary goal of stereotactic irradiation is to deliver a high dose of radiation to a small region... while ensuring rapid dose fall-off to the surrounding normal tissues."

• Cummings Otolaryngology, p. 2275

Components of the Leksell Gamma Knife (Model 4C / ICON)

Dose Delivery Terminology

• Vestibular schwannoma: 12-14 Gy to the 50% isodose line
• Glomus jugulare: 12-15 Gy to the margin
• Trigeminal neuralgia: 70-90 Gy to a 4 mm collimator shot at the trigeminal root entry zone
• Fractions: conventional RT uses 30-35 sessions (~2 Gy each); GKS uses 1 single session (or occasionally staged)

---

3. RADIOBIOLOGY

1. Direct DNA damage - high-dose radiation causes double-strand DNA breaks in tumor cells, leading to reproductive cell death
2. Vascular damage - progressive obliteration of small vessels supplying the tumor (important for AVMs and paragangliomas), leading to ischemic necrosis

---

4. TREATMENT PLANNING FLOWCHART

PATIENT REFERRED FOR GKS
          │
          ▼
   Pre-treatment Evaluation
   • MRI brain with gadolinium
   • Audiogram (pure tone average + speech discrimination)
   • Cranial nerve exam
   • Medical fitness assessment
          │
          ▼
   Stereotactic Frame Placement
   (MRI fiducial box under local/IV sedation)
          │
          ▼
   Imaging Acquisition
   • MRI with stereotactic fiducial box
   • CT if MRI contraindicated
          │
          ▼
   Treatment Planning (GammaPlan workstation)
   • 3D tumor delineation
   • Shot placement (multiple isocenters)
   • Dose prescription
   • Shielding/plugging of critical structures
   • Conformity and selectivity optimization
          │
          ▼
   Team Review (Neurotologist + Radiation Oncologist + Medical Physicist)
          │
          ▼
   Gamma Knife Treatment
   • Single session (outpatient)
   • Patient lies on treatment couch
   • Head docked in collimator helmet
   • APS moves couch through multiple shots automatically
          │
          ▼
   Frame Removal and Discharge (same day)
   Pre-medication: Dexamethasone + Ondansetron
          │
          ▼
   Follow-up
   • MRI at 6 months, 1 year, then annually
   • Repeat audiogram
   • Cranial nerve assessment

---

5. ENT INDICATIONS FOR GAMMA KNIFE SURGERY

A. VESTIBULAR SCHWANNOMA (Acoustic Neuroma) - PRIMARY INDICATION

Classification and Selection

Absolute Contraindications (Shambaugh)

• Tumor extending too far inferiorly to fit within the collimator helmet
• Large tumors causing life-threatening brainstem compression or obstructive hydrocephalus (>3 cm CPA dimension)

Patient Selection Criteria (Decision Flowchart)

VESTIBULAR SCHWANNOMA DIAGNOSED
              │
    ┌─────────┼──────────┐
    ▼         ▼          ▼
OBSERVE    GKS       MICROSURGERY
    │         │          │
Growing?  Small-medium  Large tumor
Patient   Elderly/      Young fit pt
elderly?  medically     Useful hearing
No useful unfit         aim > GKS
hearing?  Serviceable   Intracranial
CPA <3cm  hearing       hypertension
    │     desired
    └─────────→ Shared Decision Making with Patient

Outcomes of GKS in Vestibular Schwannoma

"Tumor control and facial nerve motor preservation occurs with virtually all vestibular schwannoma patients treated with current gamma knife protocols."

• Shambaugh - Surgery of the Ear, p. 721

• Greatest hearing decline occurs between 2-4 years post-GKS (not immediately)
• GKS for tinnitus - a 2024 systematic review (King et al., PMID 38892775) found variable tinnitus outcomes regardless of treatment modality; GKS shows a trend toward decreased tinnitus burden
• Cochlear dose is a critical predictor of hearing preservation; minimum cochlear dose should ideally be kept < 4 Gy

B. GLOMUS JUGULARE TUMORS (Paragangliomas)

GKS vs. Surgery for Glomus Jugulare

"A meta-analysis... Neurological deficits in those treated with gamma knife, CyberKnife or LINAC, showed no change in 58.2%, improved in 39%, and permanently worsened in 2.8%... Tumor control was achieved in approximately 98% of individuals at 39 months."

• Shambaugh - Surgery of the Ear, p. 722

• Tumor control rate: 95% (95% CI 93-97%)
• Clinical improvement rate: 47%
• Tinnitus improved in 54%, hearing loss improved in 28%
• Cranial nerve deficit improved in 22%
• Mean follow-up: 47 months

Decision Algorithm for Glomus Jugulare

GLOMUS JUGULARE DIAGNOSED
           │
    ┌──────┴──────┐
    ▼             ▼
SMALL/MEDIUM   LARGE / INTRADURAL
  TUMOR           EXTENSION
    │                │
    ▼                ▼
  GKS PRIMARY    SURGERY FIRST
  (outpatient)   + Staged GKS for
                   residual tumor
           │
           ▼
   Follow-up MRI at 6m, 1yr, annually
   (look for: reduced vascularity,
    partial shrinkage, stable volume)

C. TRIGEMINAL NEURALGIA

• 2025 Systematic Review (Hajikarimloo et al., PMID 40319265) showed SRS is effective for tumor-related trigeminal neuralgia with meaningful pain relief rates
• Benefit: completely non-invasive, no anesthesia, day-case procedure

D. OTHER ENT-RELATED INDICATIONS

E. COMPARISON: GKS vs. LINAC vs. CYBERKNIFE

---

6. THE PROCEDURE - STEP-BY-STEP

Step 1: Frame Placement

• The MRI fiducial box (smallest of the three plexiglass boxes) is attached to orient the target within the fiducial range
• Frame placed so the tumor is centrally located within the collimator helmet space
• Avoid placement in bone flaps, cranioplasty materials, burr holes, or skull defects

Step 2: Imaging

• High-resolution gadolinium-enhanced MRI with the stereotactic fiducial box attached
• This allows precise correlation between image coordinates and frame coordinates

Step 3: Treatment Planning (GammaPlan)

1. Import MRI images and build a 3D model of the tumor
2. Delineate target volume - tumor outline on each slice
3. Place shots (isocenters) within the tumor using different collimator sizes
4. Assign dose - peripheral dose usually set to 50% isodose line (typically 12-14 Gy for VS)
5. Apply plugs/shields to block beams that would irradiate critical structures (cochlea, brainstem, facial nerve, optic chiasm)
6. Optimize for conformity (dose matches tumor shape) and selectivity (minimal dose outside target)
7. Team review by neurotologist, radiation oncologist, and medical physicist

"Once the treatment plan has been determined to be appropriate by the gamma knife team (surgeon, radiation oncologist, and radiation physicist), the stereotactic coordinates and irradiation times are printed and are ready for implementation."

• Shambaugh - Surgery of the Ear, p. 523

Step 4: Treatment Delivery

• Patient positioned on the treatment couch
• Head docked into the collimator helmet
• APS automatically moves the patient through each shot position
• Each shot delivers a precisely timed burst of radiation
• Patient is awake; no anesthesia needed; procedure takes 30 min-3 hours depending on plan complexity
• Patient observes via closed-circuit TV; team communicates via intercom

Step 5: Post-Treatment

• Frame removed
• Pre-medicated with dexamethasone (reduce edema) and ondansetron (nausea)
• Observed for several hours, discharged home same day
• Follow-up MRI at 6 months, 1 year, then annually

---

7. COMPLICATIONS AND MANAGEMENT

Early (<1 week)

• Pin site pain/bleeding (frame fixation)
• Headache after frame removal
• Nausea/vomiting (pre-treat with ondansetron)
• Transient dizziness

Delayed (months-years)

---

8. OUTCOMES SUMMARY - COMPARISON WITH MICROSURGERY

                    GKS                     MICROSURGERY
                     │                            │
    ┌────────────────┼──────────┐    ┌────────────┴──────────────┐
    │                │          │    │             │              │
Tumor           Facial Nerve  Hearing    Tumor      Facial       Hearing
Control 97%     Motor >99%   50-77%    Control    Preservation  Preservation
(10 year)       preserved    at 2 yr   (resection)  60-90%      30-60%
                                       ~85-95%     (varies by
                                                    approach)

• Hospitalization: GKS = day case; Surgery = 5-10 days
• Recovery: GKS = immediate return to activities; Surgery = weeks-months
• Hearing: Both carry risk; GKS may be superior for small tumors
• Facial nerve: GKS superior (>99% vs. variable in surgery)
• Tumor removal: Surgery physically removes tumor; GKS controls growth
• Retreatment: GKS can be retreated; repeated surgery has higher morbidity

---

9. SPECIAL CONSIDERATIONS IN ENT PRACTICE

Hearing Preservation Strategy

• Cochlear dose minimization using plugging of beam channels targeting cochlea
• Modern targets: minimum cochlear dose < 4 Gy (Morshed et al., J Neurosurg 2025, PMID reference)
• Hearing aids or cochlear implants for patients with post-GKS hearing loss

NF2 (Neurofibromatosis Type 2)

• Bilateral VS requires extreme caution
• GKS preferred over surgery for the sole-hearing ear to preserve function
• Goal: arrest growth while preserving serviceable hearing as long as possible

Imaging Surveillance After GKS

TUMOR RESPONSE PATTERNS AFTER GKS (Shambaugh)
        │
   ┌────┼────────────────┐
   ▼    ▼                ▼
SHRINK  STABLE SIZE  PSEUDO-PROGRESSION
(best  (control -    (T2 signal change
result) common)      at 6-12 months;
                     usually resolves)
   ▲
   RARE FAILURE (true progression)
   → Consider microsurgery or re-GKS

---

10. RECENT ADVANCES (2020-2026)

1. Leksell Gamma Knife ICON

• First frameless GKS system using cone-beam CT (CBCT) and infrared camera for real-time tracking
• Enables hypofractionated GKS (2-5 fractions) - ideal for large tumors and hearing preservation
• Eliminates the need for stereotactic frame in selected cases
• Allows outpatient fractionated treatments (5 x 5 Gy or 3 x 7 Gy paradigms)

2. Cochlear Dose Mapping

• High-resolution MRI cochleography combined with dose planning to spare the basal turn of cochlea
• 2025 data (Morshed et al., J Neurosurg) confirms minimum cochlear dose directly impacts hearing outcomes

3. MRI-only Planning

• MRI-based synthetic CT using deep learning algorithms
• Eliminates additional CT scan radiation; reduces workflow steps

4. Artificial Intelligence in GKS Planning

• AI-assisted tumor segmentation on MRI
• Automated shot placement and dose optimization
• Reduces inter-observer variability in target delineation

5. Treatment of Large Tumors - Combined/Staged Approach

• Partial resection (decompression) followed by GKS for large VS (>3 cm)
• Reduces tumor bulk, relieves brainstem compression, then GKS controls residual
• Published paradigm: intracapsular decompression + GKS (Cummings, p. 4383)

6. Proton Beam Radiosurgery

• Proton beams offer Bragg peak dose deposition with virtually no exit dose
• Under investigation for skull base tumors adjacent to optic apparatus, brainstem
• Currently limited by equipment availability

7. Immunogenicity of GKS

• Growing evidence that high-dose focal radiation triggers tumor immunogenic cell death
• Potential synergy with immunotherapy (checkpoint inhibitors) for skull base malignancies

8. Quality of Life Outcomes

• Recent systematic reviews (Sergi et al., 2022, PMID 36294756) increasingly incorporate patient-reported outcomes (PROs), quality of life, tinnitus scales alongside tumor control rates

---

11. RGUHS UNIVERSITY - EXAM-RELEVANT SUMMARY TABLE

---

12. REFERENCES

1. Wackym PA, Runge-Samuelson CL, Friedland DR. "Gamma Knife Surgery." In: Jackler RK, Brackmann DE (eds). Shambaugh Surgery of the Ear, 6th edition, pp. 721-740. (Primary textbook reference)
2. Cummings CW et al. Cummings Otolaryngology Head and Neck Surgery, 7th edition. Chapter on Stereotactic Irradiation (Linear Accelerator, Gamma Knife, and CyberKnife), pp. 2275-2278.
3. Scott-Brown's Otorhinolaryngology Head & Neck Surgery, 8th edition, Vol. 1. Section on pituitary adenomas and skull base tumors treated with GKS.
4. Ong V et al. "Stereotactic Radiosurgery for Glomus Jugulare Tumors: Systematic Review and Meta-Analysis." World Neurosurg. 2022 Jun. PMID: 35189418 [Meta-analysis, 23 studies, 460 patients; tumor control 95%]
5. Kondziolka D, Golfinos JG. "Gamma Knife radiosurgery for vestibular schwannomas." Handb Clin Neurol. 2025. PMID: 41052848 [Review of 40+ years of GKS evolution]
6. King AM et al. "Vestibular Schwannoma and Tinnitus: A Systematic Review of Microsurgery Compared to Gamma Knife Radiosurgery." J Clin Med. 2024 May. PMID: 38892775
7. Thai NLB et al. "Treatment for vestibular schwannoma: Systematic review and single arm meta-analysis." Am J Otolaryngol. 2022 Mar-Apr. PMID: 34973662
8. Hajikarimloo B et al. "Stereotactic radiosurgery for tumor-related trigeminal neuralgia: systematic review and meta-analysis." BMC Neurol. 2025 May. PMID: 40319265
9. Sergi B et al. "Factors Influencing Personalized Management of Vestibular Schwannoma: A Systematic Review." J Pers Med. 2022. PMID: 36294756
10. Lunsford LD et al. "Radiosurgery of vestibular schwannomas: Summary of experience in 829 cases." J Neurosurg. 2005;102:195-199.

---

COMPREHENSIVE FLOWCHART: GAMMA KNIFE IN ENT - OVERVIEW

╔══════════════════════════════════════════════════════════════╗
║           GAMMA KNIFE RADIOSURGERY IN ENT                    ║
║           (Stereotactic Radiosurgery)                        ║
╚══════════════════════════════════════════════════════════════╝
                          │
     ┌────────────────────┼─────────────────────┐
     ▼                    ▼                     ▼
VESTIBULAR         GLOMUS JUGULARE         OTHER ENT
SCHWANNOMA           TUMOR               INDICATIONS
     │                    │               • CPA Meningioma
     │                    │               • Non-VS schwannoma
     ▼                    ▼               • Temporal bone mets
DOSE: 12-14 Gy     DOSE: 12-15 Gy       • Trigeminal neuralgia
50% isodose        50% isodose           • Pituitary adenoma
CONTROL: 97%       CONTROL: 95-98%       • NF2 bilateral VS
FN: >99%           CN: improved 39%
     │                    │
     └──────────┬─────────┘
                ▼
    ╔═══════════════════════╗
    ║  GKS PROCEDURE        ║
    ╠═══════════════════════╣
    ║ 1. Frame placement    ║
    ║ 2. MRI with fiducials ║
    ║ 3. GammaPlan          ║
    ║ 4. Team approval      ║
    ║ 5. Treatment delivery ║
    ║ 6. Frame removal      ║
    ╚═══════════════════════╝
                ▼
    ╔═══════════════════════╗
    ║  FOLLOW-UP MRI        ║
    ║  6m → 1yr → annually  ║
    ╠═══════════════════════╣
    ║  RESPONSES:           ║
    ║  Shrink / Stable /    ║
    ║  Pseudo-progression / ║
    ║  True progression     ║
    ╚═══════════════════════╝
                ▼
    ╔═══════════════════════╗
    ║  RECENT ADVANCES      ║
    ╠═══════════════════════╣
    ║ • GK ICON (frameless) ║
    ║ • Hypofractionation   ║
    ║ • Cochlear dose maps  ║
    ║ • AI-assisted planning║
    ║ • Proton beam SRS     ║
    ║ • Immunotherapy combo ║
    ╚═══════════════════════╝

---